Composition for Treatment of Damaged Part

• US 20130195991A1
• Filed: 03/25/2011
• Published: 08/01/2013
• Est. Priority Date: 03/26/2010
• Status: Abandoned Application

• Current Assignee: Tokushima University
• Original Assignee: Nagoya University
• Inventors: Ueda, Minoru, Yamada, Yoichi, Ebisawa, Katsumi, Yamamoto, Akihito, Sakai, Kiyoshi, Matsubara, Kohki, Hattori, Hisashi, Sugiyama, Masahiko, Inoue, Takanori
• Application Number:
  US13/637,107
• Publication Number:
  US 20130195991A1
• Time in Patent Office: Days
• US Class Current: 424/572
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 35/32 Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 38/1833 Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 38/1858 Platelet-derived growth factor [PDGF]
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 5/0664 : Dental pulp stem cells, Dental follicle stem cells

Abstract

The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.

Claims

1. A damaged part treatment composition for repairing a damaged part of a target tissue, the composition comprising a stem cell-conditioned medium obtained by culturing stem cells.

2. The damaged part treatment composition according to claim 1, which does not comprise the stem cells.

3. The damaged part treatment composition according to claim 1, wherein the stem cell-conditioned medium comprises at least two cytokines.

4. The damaged part treatment composition according to claim 1, wherein the stem cell-conditioned medium comprises at least two cytokines selected from the group consisting of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF) and transforming growth factor β

(TGF-β

).

5. The damaged part treatment composition according to claim 1, wherein the stem cells are somatic stem cells.

6. The damaged part treatment composition according to claim 1, wherein the stem cells are derived from mesenchymal stem cells.

7. The damaged part treatment composition according to claim 1, wherein the stem cells are dental pulp stem cells.

8. The damaged part treatment composition according to claim 1, which does not comprise any serum.

9. The damaged part treatment composition according to claim 1, wherein the treatment of a damaged part comprises treatment of damage to skin, periodontal tissue or bone, treatment of cerebral infarction, or treatment of a central nervous system (CNS) disease.

10. The damaged part treatment composition according to claim 1, wherein the treatment of a damaged part comprises treatment of a CNS disease, and the CNS disease is a disease or disorder selected from the group consisting of a spinal cord injury, a neurodegenerative disorder, degeneration or loss of neuronal cells and a retinal disease involving a neuronal cell disorder.

11. A method of producing the damaged part treatment composition of claim 1, the method comprising the following steps (1) to (3):

(1) a step of selecting adhesive cells from dental pulp cells;

(2) a step of culturing the adhesive cells; and

(3) a step of collecting a conditioned medium.

12. The production method according to claim 11, further comprising the following step (4):

(4) a step of subjecting the collected conditioned medium to at least one treatment selected from the group consisting of centrifugation, concentration, solvent substitution, dialysis, freezing, drying, freeze-drying, dilution, desalting and storage.

13. The production method according to claim 11, further comprising one of the following steps (a) or (b):

(a) a step of checking the collected conditioned medium with respect to the presence or absence of a neurite outgrowth activity in the presence of a nerve regeneration inhibitory substance;

or

(b) a step of checking the collected conditioned medium with respect to the presence or absence of an apoptosis inhibitory activity toward neuronal cells.

14. A damaged part treatment method for repairing a damaged part of a target tissue, the method comprising administering the damaged part treatment composition of claim 1 to a patient having the target tissue for the damaged part treatment composition, in an amount effective for repairing the damaged part of the target tissue.

15. The damaged part treatment method according to claim 14, wherein the repair of the damaged part is achieved based on an ability of endogenous stem cells.

16. The damaged part treatment method according to claim 14, wherein the damaged part treatment composition is administered by an administration method selected from the group consisting of intravenous administration, intraarterial administration, intraportal administration, intradermal administration, subcutaneous administration, intramuscular administration, intraperitoneal administration and intranasal administration.

17. A method of treating cerebral infarction comprising administering the damaged part treatment composition of claim 1 to a cerebral infarction patient, in an amount therapeutically effective for repairing a damaged part of the brain.

18. The method of treating cerebral infarction according to claim 17, wherein the damaged part treatment composition is administered by intranasal administration.

19. A method of treating a CNS disease comprising administering the damaged part treatment composition of claim 1 as a CNS disease treatment composition to a CNS disease patient, in a therapeutically effective amount.

20. The treatment method according to claim 19, wherein a dental pulp stem cell is administered to the CNS disease patient simultaneously with, or subsequently to, the administration of the CNS disease treatment composition.

21. The treatment method according to claim 20, wherein the dental pulp stem cell is an undifferentiated dental pulp stem cell that has not been subjected to differentiation-inducing treatment after acquisition thereof, or a differentiation-induced dental pulp stem cell that has been induced to differentiate into a neural cell after acquisition thereof.

22. The treatment method according to claim 19, wherein a pluripotent stem cell that has been induced to differentiate into a neural cell is administered to the CNS disease patient after the administration of the CNS disease treatment composition.

23. A method of determining whether or not a prepared dental pulp stem cell-conditioned medium is effective as an active ingredient of the CNS disease treatment composition to be employed in the CNS disease treatment method according to claim 19, the method comprising at least one of the following steps (a) or (b):

(a) a step of checking the conditioned medium with respect to the presence or absence of a neurite outgrowth activity in the presence of a nerve regeneration inhibitory substance;

or

(b) a step of checking the conditioned medium with respect to the presence or absence of an apoptosis inhibitory activity toward neuronal cells.